Level A· Stronger Clinical EvidenceSystematic ReviewEurope PMC

Modeling Immunity In Vitro: Slices, Chips, and Engineered Tissues

Hammel JH., Cook SR., Belanger MC., Munson JM., Pompano RR.

Systematic Review on Hip, published in Annu Rev Biomed Eng (2021) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Annu Rev Biomed Eng (2021)
Reported sample size
—
Source database
Europe PMC
PMID
33872520
PMCID
PMC8277680
DOI
10.1146/annurev-bioeng-082420-124920
Citations
54

Abstract (original English)

Modeling immunity in vitro has the potential to be a powerful tool for investigating fundamental biological questions, informing therapeutics and vaccines, and providing new insight into disease progression. There are two major elements to immunity that are necessary to model: primary immune tissues and peripheral tissues with immune components. Here, we systematically review progress made along three strategies to modeling immunity: ex vivo cultures, which preserve native tissue structure; microfluidic devices, which constitute a versatile approach to providing physiologically relevant fluid flow and environmental control; and engineered tissues, which provide precise control of the 3D microenvironment and biophysical cues. While many models focus on disease modeling, more primary immune tissue models are necessary to advance the field. Moving forward, we anticipate that the expansion of patient-specific models may inform why immunity varies from patient to patient and allow for the rapid comprehension and treatment of emerging diseases, such as coronavirus disease 2019.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Thymus GlandLymphocytesMacrophagesImmune SystemAnimalsHumansMiceTissue Array AnalysisTissue EngineeringMicrofluidics

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research